A Randomized Trial Comparing the Efficacy and Safety of Secukinumab with Tofacitinib in the Treatment of Moderate to Severe Hidradenitis Suppurativa in Chinese Patients
- Sponsor
- Second Affiliated Hospital, School of Medicine, Zhejiang University
- Study ID
- NCT06707246
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 75 Years
- Healthy Volunteers
- Not accepted
Interventions
- Secukinumab 300 MG; Tofacitinib 11mg — DRUGTofacitinib tablet 11mg per tablet; Secukinumab 150mg/ml
Study Details
The goal of this clinical trial is to compare the efficacy secukimumab versus tofacitinib in patients with moderate to severe hidradenitis suppurativa (HS)in adults. It will also learn about the safety of secukimumab and tofacitinib. The main questions it aims to answer are: * Which treatment is more effective in patients with moderate to severe HS? * What medical problems do participants have when taking secukimumab versus tofacitinib? Researchers will compare secukimumab versus tofacitinib to see which treatment works better to treat moderate to severe HS. Participants will: * Half of participants will take secukimumab every week in the first month and every four weeks thereafter till 1 year * Another half of participants will take tofacitinib a tablet daily for 1 year * Visit the clinic once every 2 weeks for checkups and tests in the first month, and every 4 weeks thereafter * Keep a diary of their symptoms and the number of times they use a rescue inhaler
Key Dates
- Start date
- Dec 15, 2024
- Status verified
- Oct 2024
- Primary completion
- Oct 31, 2026
- Completion
- Oct 31, 2027
Study Design
- Enrollment
- 60 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Secukinumab treatment groupParticipants will take secukinumab 300mg every week in the first month and every four weeks thereafter till 1 year
- Experimental: Tofacitinib treatment groupParticipants will take tofacitinib 11mg daily for 1 year
Primary Outcome Measure
Clinical response of HiSCR at week 12 week [ Time Frame: Week 12 ]
Central Contacts
- Jiaqi Chen, Ph.D., M.D.+86 15088687593
Related Studies
- The Ohio State University Dermatology BiorepositoryRecruiting · Ohio State University · Columbus, Ohio
- Clinical and Biological Characteristics of Hidradenitis SuppurativaRecruiting · University of California, San Francisco · San Francisco, California
- Hidradenitis Suppurativa Prospective Observational Registry and Biospecimen RepositoryRecruiting · University of California, San Francisco · San Francisco, California
- Battlefield Acupuncture for Pain in Hidradenitis SuppurativaRecruiting · Wayne State University · Dearborn, Michigan